Multiple studies have shown that combining a VEGF inhibitor with an EGFR-TKI is significantly more effective than EGFR-TKI monotherapy in patients with advanced EGFR-mutant NSCLC. Here, VEGFA is linked to non-small cell lung carcinoma.